Lilly Reports Disappointing Data On Alzheimer's Candidate
Zacks Investment Research | Feb 10, 2020 09:12PM ET
Eli Lilly and Company (NYSE:LLY) announced failure to meet endpoint in a phase II/III study on pipeline candidate, solanezumab, in patients with a rare inherited form of Alzheimer’s disease (“AD”).
The phase II/III study, DIAN-TU, is sponsored by the Washington University School of Medicine in St. Louis. The study tested two investigational therapies, solanezumab and Roche’s (OTC:RHHBY) gantenerumab compared to placebo to determine if either of these treatments could slow down the rate of cognitive decline and improve disease-related biomarkers in patients with dominantly inherited Alzheimer's disease (“DIAD”), also known as autosomal dominant Alzheimer's disease (“ADAD”). Moreover, industry ’s increase of 12.5%.
Alzheimer’s, a fatal condition that causes progressive decline in memory, has always been a highly challenging area and not much progress has been made despite significant investments (both funds and resources). Several companies, including Lilly and Roche, have failed to develop safe and effective treatment options for this deadly brain disease.
Biogen (NASDAQ:BIIB) , one of the companies with several AD candidates in its pipeline, has suffered multiple setbacks in the past couple of years and discontinued several late-stage studies. However, the company plans a regulatory filing for AD candidate, aducanumab, soon. Apart from Biogen, Novartis (NYSE:NVS) and Amgen (NASDAQ:AMGN) also discontinued two pivotal phase II/III studies evaluating their BACE1 inhibitor, CNP520, in AD patients.
Despite the setbacks, companies continue to invest heavily in developing AD treatments, given the high commercial potential in this market.
Eli Lilly and Company Price
Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.